It's been a rough Friday for BioAge Labs Inc. (NASDAQ:BIOA). The biotech's stock cratered, down more than 61% at last check, after a major trial failure from a much bigger player sent shockwaves through the world of NLRP3-targeting therapies.
The culprit? Novo Nordisk A/S (NYSE:NVO) announced that its experimental drug ziltivekimab failed to reduce the risk of major adverse cardiovascular events (MACE) compared to placebo in high-risk patients in the Phase 3 ZEUS trial. That's a big deal, not just for Novo, but for the entire class of drugs that work by inhibiting the NLRP3 inflammasome, a key driver of inflammation.
William Blair analyst Andy Hsieh was quick to point out the implications. He noted that the ZEUS results cast doubt on the assumption that large reductions in high-sensitivity C-reactive protein (hsCRP) translate into protection against cardiovascular events. That's a critical link for BioAge, whose lead candidate BGE-102 is an NLRP3 inhibitor being developed for cardiovascular disease and retinal disorders, including diabetic macular edema.
Here's the thing: Novo didn't disclose the exact hsCRP reduction in the ZEUS trial. But in a previous Phase 2 study, 15 mg of ziltivekimab cut hsCRP by 88% after 12 weeks. Hsieh said that's comparable to what BioAge saw in its Phase 1 trial of BGE-102 at once-daily doses of 60 mg and 120 mg. So if a drug that slashes hsCRP by nearly 90% doesn't help patients, what does that mean for BGE-102?
BioAge is already moving forward. It dosed the first participant in its QUELL-CV Phase 2 proof-of-concept trial in June, with top-line data expected in the second half of 2026. The company also plans to start a Phase 1b/2a proof-of-concept study in diabetic macular edema in mid-2026, with results anticipated in mid-2027. But the ZEUS failure has thrown a wrench into the narrative.
Hsieh said investors may now remove BioAge's NLRP3 opportunity from their valuation models entirely. "Despite plans to examine BGE-102 in ophthalmology indications, we believe the approach remains high risk and difficult to build an investment thesis around," William Blair wrote in a note Friday. The firm maintained its Market Perform rating on BioAge shares.
The pain isn't limited to BioAge. Neumora Therapeutics Inc. (NASDAQ:NMRA), which is developing NMRA-215, a central nervous system-penetrating NLRP3 inhibitor, also saw its stock trade lower in sympathy. Neumora recently wrapped up a 13-week repeat-dose rat toxicology study for NMRA-215 and plans to kick off a first-in-human trial by the end of 2026.
So what's the takeaway? The ZEUS trial failure is a stark reminder that in biotech, a promising mechanism on paper doesn't always translate to clinical success. For BioAge, the road ahead just got a whole lot steeper.
